Obesity in people over 65 drives disability and erodes quality of life
For decades, older adults living with obesity have occupied a quiet blind spot in medical research — too often deemed too fragile for intervention, too rarely enrolled in the trials that shape treatment. A new pooled analysis of six clinical studies now offers a measured but meaningful answer: semaglutide produces substantial, sustained weight loss in adults over 65, with a safety profile that, while not without nuance, does not fundamentally differ from what younger populations experience. In a world where obesity among the elderly quietly drives disability and lost independence, this evidence invites medicine to reconsider who deserves access to its newest tools.
- Older adults with obesity have long been undertreated — excluded from drug trials and assumed too vulnerable for aggressive weight management — leaving a major public health gap unaddressed.
- The stakes are high: obesity in people over 65 erodes independence, accelerates disability, and burdens healthcare systems, particularly in high-income countries where this age group carries a disproportionate share of excess weight.
- Across 68 weeks, semaglutide delivered a 15.4% average weight reduction in participants over 65, with more than two-thirds losing at least 10% of their body weight — results that also improved blood pressure, cholesterol, and blood sugar control.
- Serious adverse events were modestly elevated in the treatment group (19% vs. 12.7%), but feared complications like fractures and dangerous blood sugar drops remained below 1% in both groups, suggesting the risk is manageable rather than prohibitive.
- The findings point toward a meaningful expansion of semaglutide's use in elderly patients — a shift that could fundamentally change how clinicians approach obesity in their oldest and most overlooked patients.
Researchers analyzing data from six clinical trials have found that semaglutide, a once-weekly injection for obesity, produces meaningful and sustained weight loss in adults over 65 — a group historically underrepresented in drug studies and often considered too fragile for aggressive treatment.
The analysis, led by Prof. Luca Busetto of the University of Padova and colleagues including researchers from Novo Nordisk, pooled results from 358 participants aged 65 and older, excluding those with diabetes to ensure clean comparisons. Participants averaged 69 years old, weighed roughly 99 kilograms, and had a BMI of 36.6 at the outset.
After 68 weeks, those receiving semaglutide 2.4 mg lost an average of 15.4 percent of their body weight, against just 5.1 percent for placebo. Waist circumference shrank by 14.3 centimeters versus 6 centimeters. More than two-thirds of semaglutide recipients lost at least 10 percent of their starting weight; nearly half reached 15 percent; more than a quarter exceeded 20 percent. The drug also improved blood pressure, cholesterol, blood fats, and blood sugar control — and brought roughly 27 percent of treated participants to a BMI below 27, compared to just 5.5 percent on placebo.
The safety picture was largely reassuring. Overall side effect rates were similar between groups, and feared complications like fractures and dangerous blood sugar drops occurred in less than 1 percent of either group. Serious adverse events were somewhat more common with semaglutide — 19 percent versus 12.7 percent — but were considered manageable.
Busetto emphasized that obesity in older adults represents a major and underappreciated public health burden, particularly in wealthy nations. His team's findings suggest the door to effective treatment can now be opened wider for elderly patients — potentially reshaping how medicine approaches weight management in its oldest and most overlooked population.
Researchers analyzing data from multiple clinical trials have found that semaglutide, a once-weekly injection used to treat obesity, produces meaningful and sustained weight loss in people over 65—a group that has historically been underrepresented in drug studies and often dismissed as too fragile for aggressive treatment.
The analysis, led by Prof. Luca Busetto of the University of Padova and colleagues including researchers from Novo Nordisk (the drug's manufacturer), pooled results from six separate trials involving 358 participants aged 65 and older. The researchers excluded people with diabetes from this particular analysis because weight loss outcomes differ significantly in diabetic populations, making direct comparison impossible. At the start, participants averaged 69 years old, weighed about 99 kilograms, and had a BMI of 36.6—firmly in the obese range. Most were women, and the vast majority were between 65 and 74 years old.
After 68 weeks, those receiving semaglutide 2.4 mg had lost an average of 15.4 percent of their body weight, compared to just 5.1 percent in the placebo group. The drug's effect on waist circumference was similarly pronounced: a reduction of 14.3 centimeters versus 6 centimeters for placebo. More than two-thirds of semaglutide recipients shed at least 10 percent of their starting weight. Nearly half achieved a 15 percent reduction, and more than a quarter lost 20 percent or more. By contrast, only a small fraction of placebo recipients hit any of these milestones.
Beyond the scale, the drug improved several markers of heart and metabolic health. Blood pressure dropped more in the semaglutide group. Cholesterol and blood fats improved. Blood sugar control, measured by glycated hemoglobin, showed greater gains. About 27 percent of semaglutide recipients reached what researchers call a healthy weight—a BMI below 27—compared to just 5.5 percent on placebo. These improvements matter in a population where obesity drives serious complications and erodes quality of life.
The safety picture was largely reassuring, though not without caveats. The overall rate of adverse events was similar between groups—about 89 percent on semaglutide experienced some side effect, compared to 84.5 percent on placebo. Constipation and dizziness, both known effects of this class of drug, occurred more frequently with semaglutide. But serious adverse events were somewhat more common in the treatment group: 19 percent versus 12.7 percent on placebo. Fractures and dangerously low blood sugar—concerns sometimes raised about weight loss drugs in older adults—occurred in less than 1 percent of either group.
Busetto emphasized that obesity in people over 65 represents a major public health problem, particularly in wealthy nations where the majority of excess weight cases actually occur in this age group. The condition drives disability, reduces independence, and diminishes quality of life. His team's findings suggest that semaglutide can be used safely and effectively in this vulnerable population, opening a door to treatment options that were previously considered too risky or simply untested in older adults. The results support expanding access to the drug for elderly patients with obesity, a shift that could reshape how doctors approach weight management in their oldest patients.
Citas Notables
In many countries, the majority of excess weight cases occur in adults aged 65 and over, representing a major driver for obesity-related complications and an important cause of reduced quality of life and disability.— Prof. Luca Busetto, University of Padova
The safety and efficacy profile of semaglutide was consistent with that reported in the broader STEP programme.— Prof. Luca Busetto, University of Padova
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that this analysis specifically excluded people with diabetes?
Because weight loss drugs work differently in people with diabetes. The metabolic situation is fundamentally altered. If you mix those results together, you can't tell what the drug actually does in either group. You'd be comparing apples to oranges and calling it fruit.
So 358 people out of 4,523 is quite small. Does that weaken the findings?
It does make the older adult group smaller, yes. But that's partly the point—older people were barely in these trials to begin with. Eight percent representation is actually telling you something about how medicine has historically overlooked this population. The findings are real, but they're based on a subset.
The serious adverse event rate went up from 12.7 to 19 percent. That's a meaningful jump. How do we interpret that?
It's higher, and that matters. But you have to ask what those serious events actually were. The source doesn't break that down. We know fractures and low blood sugar weren't the culprits. So something else drove the difference. Without that detail, you can't say whether it's a dealbreaker or a manageable trade-off.
What does it mean that 27 percent reached a "healthy weight"?
It means they got their BMI below 27. That's a categorical shift—not just incremental improvement, but crossing into a different health category. For someone who's been obese their whole life, that's substantial. But it also means 73 percent didn't reach that threshold, even on the drug.
Why is Novo Nordisk sponsoring research on their own drug?
That's a fair question to hold. They funded it, but the analysis was led by an independent researcher at an Italian university. That doesn't eliminate bias, but it's not a company-run study either. The conflict is real and worth noting, but the data itself can still be credible.
What happens after week 68? Do people keep the weight off?
The source doesn't say. That's a crucial gap. Sustained weight loss is different from weight loss during a trial. You'd want to know what happens when people stop the injections, or whether they need to stay on it indefinitely.